Compare AU

Compare CURE vs. VACF

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Vanguard Australian Corp Fixed Interest Index ETF (VACF). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

VACF

Popularity

Low

Low

Pearlers invested

80

8

Median incremental investment

$620.00

$2,493.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,298.77

$3,234.42

Average age group

> 35

26 - 35


Key Summary

CURE

VACF

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

VACF.AX was created on 2014-10-10 by Vanguard. The fund's investment portfolio concentrates primarily on investment grade fixed income. Vanguard Australian Corporate Fixed Interest Index Fund seeks to track the return of the Bloomberg AusBond Credit 0+ Yr Index before taking into account fees, expenses and tax.

Top 3 holdings

AbbVie Inc (2.62 %)

Alnylam Pharmaceuticals Inc (2.59 %)

Amgen Inc (2.59 %)

Kommunalbanken AS 4.25 2025-07-16 (1.09 %)

CPPIB Capital Inc. 4.2 2028-05-02 (0.95 %)

CPPIB Capital Inc. 4.45 2027-09-01 (0.95 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.29 %


Key Summary

CURE

VACF

Issuer

Global X

Vanguard

Tracking index

S&P Biotechnology Select Industry

Bloomberg AusBond Credit (0+Y) Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.29 %

Price

$49.01

$51.34

Size

$34.191 million

$1.494 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

2.15 %

Market

ASX

ASX

First listed date

12/11/2018

25/05/2016

Purchase fee

$6.50

$6.50


Community Stats

CURE

VACF

Popularity

Low

Low

Pearlers invested

80

8

Median incremental investment

$620.00

$2,493.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,298.77

$3,234.42

Average age group

> 35

26 - 35


Pros and Cons

CURE

VACF

Pros

  • Higher exposure to US market

  • Higher distribution yield

  • Lower management fee

  • Higher price growth

Cons

  • Higher management fee

  • Lower price growth

  • Lower exposure to US market

  • Lower distribution yield

CURE

VACF

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home